Levofloxacin Hemihydrate

Mechanism of Action

Levofloxacin inhibits bacterial type II topoisomerases, topoisomerase IV and DNA gyrase. Levofloxacin, like other fluoroquinolones, inhibits the A subunits of DNA gyrase, two subunits encoded by the gyrA gene. This results in strand breakage on a bacterial chromosome, supercoiling, and resealing; DNA replication and transcription is inhibited.

Indication

LEVAQUIN® is a fluoroquinolone antibacterial indicated in adults (18 years of age and older) with infections caused by designated, susceptible bacteria and in pediatric patients where indicated. 

• Pneumonia: Nosocomial and Community Acquired 
• Skin and Skin Structure Infections (SSSI): Complicated and Uncomplicated 
• Chronic bacterial prostatitis
• Inhalational Anthrax, Post-Exposure in adult and pediatric patients
• Plague in adult and pediatric patients
• Urinary Tract Infections (UTI): Complicated and Uncomplicated
• Acute Pyelonephritis 
• Acute Bacterial Exacerbation of Chronic Bronchitis
• Acute Bacterial Sinusitis

Usage:

To reduce the development of drug-resistant bacteria and maintain the effectiveness of LEVAQUIN® and other antibacterial drugs, LEVAQUIN® should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria IQUIX® solution is a topical quinolone antimicrobial indicated for the treatment of corneal ulcer caused by susceptible strains of the following bacteria: 

• Corynebacterium species* 
• Staphylococcus aureus 
• Staphylococcus epidermidis 
• Streptococcus pneumonia 
• Viridans group streptococci* 
• Pseudomonas aeruginosa 
• Serratia marcescens*

Dr. Reddy's Expertise

Headquartered in Hyderabad, India, Dr. Reddy's Laboratories is one of the leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Levofloxacin Hemihydrate API. Dr. Reddy's API business is a preferred partner to pharma companies across the US, Europe, Brazil, Latin America, Japan, China, Korea, Middle East and other emerging markets.

Dr. Reddy's API business thrives on the deep technical strengths established over the last 30+ years in the development and manufacture of complex APIs such as steroids, peptides, complex long chain molecules and highly potent APIs (HPAPIs / oncology drugs). This expertise is complemented by our prowess in intellectual property and regulatory affairs which helps us consistently meet and exceed regulatory standards. Dr. Reddy's Levofloxacin Hemihydrate API is the outcome of the extensive expertise in R&D, IP, and Regulatory.

A key component in helping our customers be first to market is a responsive supply chain. We achieve this by making sure that all our facilities are operating efficiently and to the latest standards of quality, safety, and productivity. A strong interconnect between business and factories allows for a quick reaction to dynamic market changes, so that we can avert shortages and meet sudden surges in demand.